
Edwards Lifesciences Corporation Revenue | EW
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.07 B | 5.44 B | 5.01 B | 4.46 B | 5.23 B | 4.39 B | 4.35 B | 3.72 B | 3.44 B | 2.96 B | 2.49 B | 2.32 B | 2.05 B | 1.9 B | 1.68 B | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.07 B | 1.68 B | 3.7 B |
Quarterly Revenue Edwards Lifesciences Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 B | 1.74 B | 1.65 B | 1.57 B | 1.55 B | 1.53 B | 1.41 B | 1.39 B | 1.35 B | 1.37 B | 1.33 B | 1.27 B | 1.24 B | 1.28 B | 1.22 B | 430 M | 1.32 B | 1.37 B | 1.34 B | 1.33 B | 1.31 B | 1.38 B | 1.22 B | 1.19 B | 1.14 B | 925 M | 1.13 B | 1.17 B | 1.09 B | 1.09 B | 993 M | 978 M | 907 M | 944 M | 895 M | 888 M | 822 M | 842 M | 884 M | 768 M | 739 M | 759 M | 697 M | 671 M | 616 M | 617 M | 590 M | 618 M | 607 M | 575 M | 522 M | 536 M | 496 M | 517 M | 497 M | 510 M | 448 M | 482 M | 459 M | 430 M | 413 M | 431 M | 404 M | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.74 B | 404 M | 962 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Nemaura Medical
NMRD
|
77 K | - | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
97.6 M | $ 6.11 | 6.0 % | $ 1.51 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Zimmer Biomet Holdings
ZBH
|
8.23 B | $ 103.42 | 1.3 % | $ 20.5 B | ||
|
Abbott Laboratories
ABT
|
44.3 B | $ 104.47 | -0.23 % | $ 182 B | ||
|
Align Technology
ALGN
|
4.03 B | $ 163.89 | 0.26 % | $ 11.9 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 7.08 | 1.95 % | $ 1.06 B | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 43.66 | 1.45 % | $ 64.6 B | ||
|
Cognyte Software Ltd.
CGNT
|
400 M | $ 7.93 | 1.34 % | $ 578 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 5.05 | -0.59 % | $ 3.4 M | ||
|
Bio-Rad Laboratories
BIO
|
2.58 B | $ 369.72 | 3.22 % | $ 10.1 B | ||
|
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.44 | -4.5 % | $ 100 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 48.11 | -0.59 % | $ 1.49 B | ||
|
Establishment Labs Holdings
ESTA
|
211 M | $ 70.8 | 1.86 % | $ 2.1 B | ||
|
Medtronic PLC
MDT
|
36.4 B | $ 100.7 | -1.58 % | $ 129 B | ||
|
Myomo
MYO
|
40.9 M | $ 0.88 | -3.85 % | $ 36.8 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.2 | 0.63 % | $ 473 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 19.7 | 1.7 % | $ 706 M | ||
|
Electromed
ELMD
|
73.8 M | $ 23.59 | 1.99 % | $ 195 M | ||
|
Inogen
INGN
|
349 M | $ 5.58 | -1.85 % | $ 148 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 70.5 | 0.73 % | $ 9.53 B | ||
|
Quanterix Corporation
QTRX
|
139 M | $ 2.07 | -27.62 % | $ 88.3 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 82.34 | -1.33 % | $ 1.05 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
13 M | $ 0.26 | -8.45 % | $ 16.8 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 7.77 | -1.21 % | $ 220 M | ||
|
Accuray Incorporated
ARAY
|
402 M | $ 2.49 | 2.05 % | $ 305 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
AxoGen
AXGN
|
225 M | $ 56.98 | 2.9 % | $ 2.62 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.5 | -28.53 % | $ 8.47 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 5.1 | 12.83 % | $ 317 M | ||
|
Sensus Healthcare
SRTS
|
27.5 M | $ 2.3 | 1.55 % | $ 37.6 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 318.0 | 0.14 % | $ 122 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.64 B | $ 13.87 | 2.32 % | $ 1.06 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 26.45 | 1.54 % | $ 605 M | ||
|
Bruker Corporation
BRKR
|
3.44 B | $ 63.28 | 3.13 % | $ 9.61 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 94.44 | 2.74 % | $ 5.15 B | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 16.97 | -0.53 % | $ 1.15 B | ||
|
Profound Medical Corp.
PROF
|
16.1 M | $ 6.87 | -2.97 % | $ 208 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 4.91 | -0.07 % | $ 58.7 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 6.59 | -1.27 % | $ 261 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 2.69 | -1.83 % | $ 109 M | ||
|
InspireMD
NSPR
|
8.98 M | $ 0.68 | 4.58 % | $ 43.7 M | ||
|
InMode Ltd.
INMD
|
370 M | $ 12.87 | -0.43 % | $ 832 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 31.67 | 0.81 % | $ 743 M | ||
|
Outset Medical
OM
|
119 M | $ 3.04 | -3.8 % | $ 46.2 M | ||
|
PAVmed
PAVM
|
71 K | $ 1.3 | -13.91 % | $ 872 K | ||
|
AVITA Medical
RCEL
|
71.6 M | $ 16.71 | 5.96 % | $ 466 M |